Abstract The development of resistance to chemotherapeutics is still a severe event in cancer patients. One of the major obstacles to the effectiveness of cancer therapies is the development of side effects and resistance to therapy. The characterization of novel biomarkers that support a more aggressive phenotype may provide new diagnostic tools and new opportunities for cancer therapy. In the context of breast cancer disease, the phosphorylated form of Translationally controlled tumor protein (phospho-TCTP) appears a new prognostic factor for aggressive breast cancer and tumor progression. Dihydroartemisinin (DHA) is a novel approach to molecular targeted therapies, or combination regimens in advance breast cancer.
Phospho-TCTP and Dihydroartemisinin: A Novel Therapeutic Opportunity in Advance Breast Cancer
Maria Lucibello;
2016
Abstract
Abstract The development of resistance to chemotherapeutics is still a severe event in cancer patients. One of the major obstacles to the effectiveness of cancer therapies is the development of side effects and resistance to therapy. The characterization of novel biomarkers that support a more aggressive phenotype may provide new diagnostic tools and new opportunities for cancer therapy. In the context of breast cancer disease, the phosphorylated form of Translationally controlled tumor protein (phospho-TCTP) appears a new prognostic factor for aggressive breast cancer and tumor progression. Dihydroartemisinin (DHA) is a novel approach to molecular targeted therapies, or combination regimens in advance breast cancer.| File | Dimensione | Formato | |
|---|---|---|---|
|
prod_355027-doc_115190.pdf
accesso aperto
Descrizione: Phospho-TCTP and Dihydroartemisinin: A Novel Therapeutic Opportunity in Advance Breast Cancer
Tipologia:
Versione Editoriale (PDF)
Dimensione
289.32 kB
Formato
Adobe PDF
|
289.32 kB | Adobe PDF | Visualizza/Apri |
|
prod_355027-doc_115191.pdf
accesso aperto
Descrizione: Editor invitation letter
Tipologia:
Versione Editoriale (PDF)
Dimensione
33.4 kB
Formato
Adobe PDF
|
33.4 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
